Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.35 EUR
−26.22 M EUR
1.27 M EUR
89.14 M
About GENSIGHT BIOLOGICS
Sector
CEO
Laurence Rodriguez
Headquarters
Paris
Website
Founded
2012
ISIN
FR0013183985
FIGI
BBG00DBB2XW4
GenSight Biologics SA is a clinical-stage gene therapy company, which engages in research and development of novel therapies for mitochondrial and neurodegenerative diseases of the eye. It also focuses on central nervous system diseases. The company was founded by Bernard Jacques Alex Gilly, Botond Roska, Jean Bennett, Connie Cepko, Luk H. Vandenberghe, Serge Picaud and Jose-Alain Sahel in 2012 and is headquartered in Paris, France.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of G49N is 0.31 EUR — it has decreased by −5.38% in the past 24 hours. Watch GENSIGHT BIOLOGICS SA stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on GETTEX exchange GENSIGHT BIOLOGICS SA stocks are traded under the ticker G49N.
G49N stock has risen by 9.80% compared to the previous week, the month change is a 33.33% rise, over the last year GENSIGHT BIOLOGICS SA has showed a −52.49% decrease.
We've gathered analysts' opinions on GENSIGHT BIOLOGICS SA future price: according to them, G49N price has a max estimate of 0.36 EUR and a min estimate of 0.36 EUR. Watch G49N chart and read a more detailed GENSIGHT BIOLOGICS SA stock forecast: see what analysts think of GENSIGHT BIOLOGICS SA and suggest that you do with its stocks.
G49N reached its all-time high on Dec 8, 2008 with the price of 1,124,624.00 EUR, and its all-time low was 0.001 EUR and was reached on Nov 22, 2007. View more price dynamics on G49N chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
G49N stock is 18.69% volatile and has beta coefficient of 1.12. Track GENSIGHT BIOLOGICS SA stock price on the chart and check out the list of the most volatile stocks — is GENSIGHT BIOLOGICS SA there?
Today GENSIGHT BIOLOGICS SA has the market capitalization of 35.70 M, it has decreased by −3.48% over the last week.
Yes, you can track GENSIGHT BIOLOGICS SA financials in yearly and quarterly reports right on TradingView.
GENSIGHT BIOLOGICS SA is going to release the next earnings report on Mar 21, 2025. Keep track of upcoming events with our Earnings Calendar.
G49N net income for the last half-year is −5.85 M EUR, while the previous report showed −14.24 M EUR of net income which accounts for 58.93% change. Track more GENSIGHT BIOLOGICS SA financial stats to get the full picture.
No, G49N doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 26, 2024, the company has 16.00 employees. See our rating of the largest employees — is GENSIGHT BIOLOGICS SA on this list?
Like other stocks, G49N shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade GENSIGHT BIOLOGICS SA stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So GENSIGHT BIOLOGICS SA technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating GENSIGHT BIOLOGICS SA stock shows the sell signal. See more of GENSIGHT BIOLOGICS SA technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.